NSC 109555 | 15427-93-7 | xxxx

MedKoo Cat#: 581364 | Name: NSC 109555

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NSC109555 is a selective inhibitor of Chk2 (IC50 = 310 nM).

Chemical Structure

NSC 109555

CAS#15427-93-7

Theoretical Analysis

MedKoo Cat#: 581364

Name: NSC 109555

CAS#: 15427-93-7

Chemical Formula: C21H32N10O7S2

Exact Mass: 600.1897

Molecular Weight: 600.67

Elemental Analysis: C, 41.99; H, 5.37; N, 23.32; O, 18.64; S, 10.67

Price and Availability

Size	Price	Availability
10mg	USD 295.00	2 Weeks
25mg	USD 550.00	2 Weeks
50mg	USD 900.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

NSC 109555; DDUG dimethanesulfonate; DDUG diMS; NSC-109555; NSC109555;

IUPAC/Chemical Name

(2E,2'E)-2,2'-(((carbonylbis(azanediyl))bis(4,1-phenylene))bis(ethan-1-yl-1-ylidene))bis(hydrazine-1-carboximidamide) dimethanesulfonate

InChi Key

HXDBGZUARNKHBV-XMDRLFCYSA-N

InChi Code

InChI=1S/C19H24N10O.2CH4O3S/c1-11(26-28-17(20)21)13-3-7-15(8-4-13)24-19(30)25-16-9-5-14(6-10-16)12(2)27-29-18(22)23;2*1-5(2,3)4/h3-10H,1-2H3,(H4,20,21,28)(H4,22,23,29)(H2,24,25,30);2*1H3,(H,2,3,4)/b26-11+,27-12+;;

SMILES Code

C\C(=N/NC(=N)N)\c1ccc(NC(=O)Nc2ccc(cc2)\C(=N\NC(=N)N)\C)cc1.CS(=O)(=O)O.CS(=O)(=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

NSC109555 is a selective inhibitor of Chk2 (IC50 = 310 nM).

In vitro activity:

In vitro data show the specific inhibition of Chk2 kinase activity by NSC 109555 using in vitro kinase assays and kinase-profiling experiments. NSC 109555 was shown to be a competitive inhibitor of Chk2 with respect to ATP, which was supported by docking of NSC 109555 into the ATP binding pocket of the Chk2 catalytic domain. The potency of NSC 109555 was comparable with that of other known Chk2 inhibitors, such as debromohymenialdisine and 2-arylbenzimidazole. Reference: Mol Pharmacol. 2007 Oct;72(4):876-84. https://pubmed.ncbi.nlm.nih.gov/17616632/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMF	2.0	3.33
	DMSO	20.0	33.30
	Ethanol	3.0	4.99
	PBS (pH 7.2)	10.0	16.65

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 600.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zhu L, Zhao L, Wang H, Wang Y, Pan D, Yao J, Li Z, Wu G, Guo Q. Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest. Toxicol Lett. 2013 May 23;219(2):107-15. doi: 10.1016/j.toxlet.2013.01.019. Epub 2013 Mar 5. PMID: 23470866. 2. Jobson AG, Cardellina JH 2nd, Scudiero D, Kondapaka S, Zhang H, Kim H, Shoemaker R, Pommier Y. Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol Pharmacol. 2007 Oct;72(4):876-84. doi: 10.1124/mol.107.035832. Epub 2007 Jul 6. Erratum in: Mol Pharmacol. 2008 Oct;74(4):1170. PMID: 17616632.

In vitro protocol:

In vivo protocol:

TBD

1: Zhu L, Zhao L, Wang H, Wang Y, Pan D, Yao J, Li Z, Wu G, Guo Q. Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest. Toxicol Lett. 2013 May 23;219(2):107-15. doi: 10.1016/j.toxlet.2013.01.019. Epub 2013 Mar 5. PubMed PMID: 23470866. 2: Gogineni VR, Nalla AK, Gupta R, Dinh DH, Klopfenstein JD, Rao JS. Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells. Cancer Lett. 2011 Dec 26;313(1):64-75. doi: 10.1016/j.canlet.2011.08.022. Epub 2011 Sep 6. Erratum in: Cancer Lett. 2014 Jul 28;349(2):155. PubMed PMID: 21945852; PubMed Central PMCID: PMC3196767. 3: Jobson AG, Lountos GT, Lorenzi PL, Llamas J, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH 2nd, Yoo SS, Monks A, Self C, Waugh DS, Shoemaker RH, Pommier Y. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther. 2009 Dec;331(3):816-26. doi: 10.1124/jpet.109.154997. Epub 2009 Sep 9. PubMed PMID: 19741151; PubMed Central PMCID: PMC2784710. 4: Lountos GT, Tropea JE, Zhang D, Jobson AG, Pommier Y, Shoemaker RH, Waugh DS. Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Sci. 2009 Jan;18(1):92-100. doi: 10.1002/pro.16. PubMed PMID: 19177354; PubMed Central PMCID: PMC2708046. 5: Jobson AG, Cardellina JH 2nd, Scudiero D, Kondapaka S, Zhang H, Kim H, Shoemaker R, Pommier Y. Identification of a Bis-guanylhydrazone [4,4'-Diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol Pharmacol. 2007 Oct;72(4):876-84. Epub 2007 Jul 6. Erratum in: Mol Pharmacol. 2008 Oct;74(4):1170. PubMed PMID: 17616632. 6: Marcus SL, Nathan HC, Hutner SH, Bacchi CJ. Polyamines antagonize both the antileukemic activity and the reverse transcriptase stimulatory activity of 4,4'-diacetyldiphenylurea bis(guanylhydrazone) (DDUG). Biochem Biophys Res Commun. 1987 Jan 30;142(2):422-7. PubMed PMID: 2434093. 7: Byczkowski JZ, Porter CW. Interactions between bis(guanylhydrazones) and polyamines in isolated mitochondria. Gen Pharmacol. 1983;14(6):615-21. PubMed PMID: 6689308. 8: Byczkowski JZ, Zychlinski L, Porter CW. Potentiation of the antimitochondrial and antiproliferative effects of bis(guanylhydrazones) by phenethylbiguanide. Cancer Res. 1982 Sep;42(9):3592-5. PubMed PMID: 6896674. 9: Byczkowski JZ, Salamon W, Harlos JP, Porter CW. Actions of bis(guanylhydrazones) on isolated rat liver mitochondria. Biochem Pharmacol. 1981 Oct;30(20):2851-60. PubMed PMID: 6895596. 10: Mikles-Robertson F, Dave C, Porter CW. Apparent autophagocytosis of mitochondria in L1210 leukemia cells treated in vitro with 4,4'-diacetyl-diphenylurea-bis(guanylhydrazone). Cancer Res. 1980 Apr;40(4):1054-61. PubMed PMID: 6892613.